TrialSignal
Clinical trial intelligence report
Long-acting Exenatide: a Tool to Stop Cognitive Decline in Dysglycemic Patients With Mild Cognitive Impairment?
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT02847403-Jul 28, 2026
NCT ID
NCT02847403
Status
UNKNOWN
Phase
PHASE3
Sponsor
Azienda Ospedaliero-Universitaria di Parma
Executive brief
Investment-Ready Snapshot
Long-acting Exenatide: a Tool to Stop Cognitive Decline in Dysglycemic Patients With Mild Cognitive Impairment? is a PHASE3 clinical asset sponsored by Azienda Ospedaliero-Universitaria di Parma in Dysglycemia, Cognitive Deficit. SEO and diligence focus: Exenatide, placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02847403
Indication
Dysglycemia
Modality
small molecule
Target
Exenatide, placebo
Intervention
Exenatide, placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.